Christopher Walsh

6.0k total citations · 1 hit paper
101 papers, 4.9k citations indexed

About

Christopher Walsh is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Christopher Walsh has authored 101 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Molecular Biology, 32 papers in Hematology and 30 papers in Genetics. Recurrent topics in Christopher Walsh's work include Virus-based gene therapy research (28 papers), Hemophilia Treatment and Research (28 papers) and CRISPR and Genetic Engineering (20 papers). Christopher Walsh is often cited by papers focused on Virus-based gene therapy research (28 papers), Hemophilia Treatment and Research (28 papers) and CRISPR and Genetic Engineering (20 papers). Christopher Walsh collaborates with scholars based in United States, Netherlands and France. Christopher Walsh's co-authors include Hengjun Chao, Michaël Thomas, Lawrence R. DeChatelet, B. Moseley Waite, R. Jude Samulski, Yuanbo Liu, David R. Light, Robin W. Spencer, Chengwen Li and Joseph E. Rabinowitz and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Christopher Walsh

100 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Enzymatic Reaction Mechanisms

1978 659 citations Christopher Walsh profile →

Peers

Countries citing papers authored by Christopher Walsh

Since Specialization

Citations

This map shows the geographic impact of Christopher Walsh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Walsh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Walsh more than expected).

Fields of papers citing papers by Christopher Walsh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Walsh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Walsh. The network helps show where Christopher Walsh may publish in the future.

Co-authorship network of co-authors of Christopher Walsh

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Walsh. A scholar is included among the top collaborators of Christopher Walsh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Walsh. Christopher Walsh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Growth Hormone Receptor Antagonist Markedly Improves Gemcitabine Response in a Mouse Xenograft Model of Human Pancreatic Cancer 2024 ·International Journal of Molecular Sciences ·Reetobrata Basu, (unknown), (unknown), Silvana Duran‐Ortiz, (unknown), (unknown), Emily F. Davis-Marcisak, Christopher Walsh, (unknown), (unknown), (unknown), Uday Sandbhor, Sebastian Neggers, John J. Kopchick	2
2	A systematic review of adeno‐associated virus gene therapy clinical trials for HIV – A potential solution for patients with haemophilia and HIV? 2023 ·Haemophilia ·Sarina Levy‐Mendelovich, Christopher Walsh, Jonathan Schapiro, Shelly Soffer, Eyal Klang, Gili Kenet	1
3	Identified unmet needs and proposed solutions in mild‐to‐moderate haemophilia: A summary of opinions from a roundtable of haemophilia experts 2021 ·Haemophilia ·Christopher Walsh, Lisa Boggio, (unknown), Rachel J. Miller, (unknown), (unknown), (unknown), (unknown), Kim Baumann, (unknown), Mark W. Skinner, (unknown), (unknown), (unknown), (unknown), Michelle Witkop, (unknown), David L. Cooper	9
4	BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression 2020 ·Blood ·Barbara A. Konkle, Christopher Walsh, Miguel A. Escobar, Neil C. Josephson, Guy Young, Annette von Drygalski, Scott McPhee, R. Jude Samulski, Ivan Bilić, Maurus de la Rosa, Birgit M. Reipert, Hanspeter Rottensteiner, Friedrich Scheiflinger, John Chapin, Bruce M. Ewenstein, Paul E. Monahan	138
5	Impact of inhibitors on hemophilia a mortality in the United States 2015 ·American Journal of Hematology ·Christopher Walsh, J. Michael Soucie, Connie H. Miller	122
6	Phenotypes of Allo- and Autoimmune Antibody Responses to FVIII Characterized by Surface Plasmon Resonance 2013 ·PLoS ONE ·Kenneth B. Lewis, Richard J. Hughes, Melinda S. Epstein, Neil C. Josephson, Christine L. Kempton, Craig M. Kessler, Nigel S. Key, Tom E. Howard, Rebecca Kruse‐Jarres, Jeanne M. Lusher, Christopher Walsh, Raymond G. Watts, Ruth A. Ettinger, Kathleen P. Pratt, (unknown)	18
7	Hemophilia clinical gene therapy: brief review 2013 ·Translational research ·Christopher Walsh, (unknown)	12
8	Targeted integration of a rAAV vector into the AAVS1 region 2012 ·Virology ·Peter Ward, Christopher Walsh	16
9	Patient/Caregiver‐reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE) 2011 ·Haemophilia ·Guy Young, Amy D. Shapiro, Christopher Walsh, Ralph A. Gruppo, Robert Gut, David L. Cooper	22
10	Chimeric AAV Cap sequences alter gene transduction 2009 ·Virology ·Peter Ward, Christopher Walsh	8
11	RNA repair for haemophilia A 2006 ·Expert Reviews in Molecular Medicine ·Hengjun Chao, Christopher Walsh	93
12	New high‐technology products for the treatment of haemophilia 2004 ·Haemophilia ·Steven W. Pipe, (unknown), Christopher Walsh	22
13	RNA repair using spliceosome-mediated RNA trans-splicing 2004 ·Trends in Molecular Medicine ·S. Gary Mansfield, Hengjun Chao, Christopher Walsh	30
14	Gene therapy for hemophilia: are viral vectors really feasible? 2003 ·Journal of Thrombosis and Haemostasis ·Christopher Walsh	5
15	Restoration of Human β-Globin Gene Expression in Murine and Human IVS2–654 Thalassemic Erythroid Cells by Free Uptake of Antisense Oligonucleotides 2002 ·Molecular Pharmacology ·Thipparat Suwanmanee, Halina Sierakowska, Giuseppina Lacerra, Saovaros Svasti, Suzanne L. Kirby, Christopher Walsh, Suthat Fucharoen, Ryszard Kole	54
16	Several Log Increase in Therapeutic Transgene Delivery by Distinct Adeno-Associated Viral Serotype Vectors 2000 ·Molecular Therapy ·Hengjun Chao, Yuanbo Liu, Joseph E. Rabinowitz, Chengwen Li, R. Jude Samulski, Christopher Walsh	302
17	A deficiency in a 230 kDa DNA repair protein in Fanconi anemia complementation group A cells is corrected by the FANCA cDNA 1999 ·Carcinogenesis ·(unknown), Laura McMahon, (unknown), (unknown), Christopher Walsh, Muriel W. Lambert	20
18	Retroviral gene transfer for the assignment of Fanconi anemia (FA) patients to a FA complementation group 1998 ·Human Genetics ·(unknown), (unknown), (unknown), Martin Digweed, Johnson M. Liu, Christopher Walsh	8
19	The Fanconi Anemia Complementation Group C Gene (FAC) Suppresses Transformation of Mutant Fibroblasts by the SV40 Virus 1996 ·Biochemical and Biophysical Research Communications ·(unknown), J. A. Poiley, Marcel P. Devetten, Sachiko Kajigaya, Christopher Walsh	9
20	Retroviral-mediated Transduction of the Fanconi Anemia C Complementing (FACC) Gene in Two Murine Transplantation Models 1995 ·Blood Cells Molecules and Diseases ·J M Liu, (unknown), Christopher Walsh	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact